Pain Management Drug Panel by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine
Useful for general testing in contexts of compliance and/or abuse primarily in the pain management population. Testing is qualitative and uses a combination of mass spectrometry as well as immunoassays with documented low false positive rates.
Secondary testing is generally not indicated but is available if confirmation or quantitation is desired. If interpretation is required, refer to Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288). For a traditional screen with reflex to confirmation/quantitation testing, refer to Pain Management Panel, Screen with Reflex to Quantitation (2012312).
Qualitative Liquid Chromatography/Time of Flight Mass Spectrometry or Tandem Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years
Effective November 17, 2014
Drugs covered and range of cutoff concentrations.
Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.
||Range of Cutoff Concentrations
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem
|20 - 60 ng/mL|
|Cannabinoids (11-nor-9-carboxy-THC)||20 ng/mL|
|Ethyl Glucuronide||500 ng/mL|
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol
|Phencyclidine (PCP)||25 ng/mL|
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Time-of-Flight-Mass Spectrometry or Tandem Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
No compliance statements are in use for this test.
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
|Component Test Code*||Component Chart Name||LOINC|
|2007636||Codeine (cutoff 40 ng/mL)||3507-1|
|2007637||Morphine (cutoff 20 ng/mL)||3830-7|
|2007638||6-acetylmorphine (cutoff 20 ng/mL)||10976-9|
|2007640||Oxycodone (cutoff 40 ng/mL)||10998-3|
|2007641||Noroxycodone (cutoff 100 ng/mL)||61424-8|
|2007642||Oxymorphone (cutoff 40 ng/mL)||11247-4|
|2007643||Noroxymorphone (cutoff 100 ng/mL)|
|2007644||Hydrocodone (cutoff 40 ng/mL)||12308-3|
|2007646||Norhydrocodone (cutoff 100 ng/mL)||61421-4|
|2007647||Hydromorphone (cutoff 40 ng/mL)||9834-3|
|2007649||Buprenorphine (cutoff 5 ng/mL)||3414-0|
|2007651||Norbuprenorphine (cutoff 20 ng/mL)||58362-5|
|2007652||Fentanyl (cutoff 2 ng/mL)||11235-9|
|2007653||Norfentanyl (cutoff 2 ng/mL)||43199-9|
|2007654||Meperidine metabolite (cutoff 50 ng/mL)||3746-5|
|2007655||Tapentadol (cutoff 100 ng/mL)||72485-6|
|2007656||Tapentadol-o-Sulf (cutoff 200 ng/mL)|
|2007658||Methadone (cutoff 150 ng/mL)||3773-9|
|2007659||Propoxyphene (cutoff 300 ng/mL)||19141-1|
|2007660||Tramadol (cutoff 200 ng/mL)||43219-5|
|2007662||Amphetamine (cutoff 100 ng/mL)||19343-3|
|2007663||Methamphetamine (cutoff 400 ng/mL)||3779-6|
|2007664||MDMA- Ecstasy (cutoff 200 ng/mL)||14267-9|
|2007665||MDA (cutoff 200 ng/mL)||42253-5|
|2007666||MDEA- Eve (cutoff 200 ng/mL)||61048-5|
|2007668||Phentermine (cutoff 100 ng/mL)||3957-8|
|2007670||Benzoylecgonine (cutoff 150 ng/mL)||3393-6|
|2007672||Alprazolam (cutoff 40 ng/mL)||9351-8|
|2007673||Alpha-OH-Alprazolam (cutoff 20 ng/mL)||61036-0|
|2007674||Clonazepam (cutoff 20 ng/mL)||19245-0|
|2007675||7-Aminoclonazepam (cutoff 40 ng/mL)||61030-3|
|2007676||Diazepam (cutoff 50 ng/mL)||3550-1|
|2007677||Nordiazepam (cutoff 50 ng/mL)||3861-2|
|2007678||Oxazepam (cutoff 50 ng/mL)||12361-2|
|2007679||Temazepam (cutoff 50 ng/mL)||61060-0|
|2007680||Lorazepam (cutoff 60 ng/mL)||18187-5|
|2007681||Midazolam (cutoff 20 ng/mL)||19585-9|
|2007682||Zolpidem (cutoff 20 ng/mL)||33338-5|
|2007684||Barbiturates (cutoff 200 ng/mL)||3377-9|
|2007687||Ethyl Glucuronide (cutoff 500 ng/mL)||55349-5|
|2007688||Marijuana Metabolite (cutoff 20 ng/mL)||3435-5|
|2007689||PCP (cutoff 25 ng/mL)||3936-2|
|2007690||Carisoprodol (cut-off 100 ng/mL)||21142-5|
|2007691||Pain Management Drug Panel||8251-1|
|2008312||EER Pain Mgt Drug Pan, Mass Spec/EMITU||11526-1|
|2013281||Methylphenidate (cutoff 100 ng/mL)||3808-3|
- Comprehensive hybrid, TOF, high res, high-res
- Pain management, (drug screen, targeted, urine)